The evolution of assays for immuno-oncology research
Drug Discovery World
FEBRUARY 15, 2023
Further discovery of PD-1 and CTLA4 as negative immune regulators led to the development of a new class of cancer therapeutics, namely the immune checkpoint inhibitors 5,6. Between 2017 and 2020, the number of IO therapies being developed has increased significantly from 2030 (for 265 targets) to 4,720 (for 504 targets).
52 
Let's personalize your content